Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (170) Apply Press releases filter
- Basic page (37) Apply Basic page filter
- Pipeline (19) Apply Pipeline filter
- Corporate presentations (17) Apply Corporate presentations filter
- Shareholder meeting (17) Apply Shareholder meeting filter
- Team member (15) Apply Team member filter
- Event (14) Apply Event filter
- Videos (14) Apply Videos filter
- Financial reports (9) Apply Financial reports filter
- Analyst (7) Apply Analyst filter
- Investor contact (6) Apply Investor contact filter
- Webcasts and audio (6) Apply Webcasts and audio filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
Recruitment privacy policy
Oxford BioMedica Directors and Management
Information on the Oxford BioMedica Directors and Senior Management can be found here.
Media contact details
If you have a general media enquiry, please contact:
LentiVector platform
The LentiVector® platform is the only commercially approved lentiviral-based gene delivery system.
The TRiP System
The TRiP SystemTM maximises viral vector production output and standardises downstream process
Packaging and producer cell lines
Oxford BioMedica has developed packaging and inducible producer cell lines that enable a simplified and scalable manufacturing process whil
Analytical methods
Oxford BioMedica has developed and optimised all the analytics necessary to support product commercialisation.
Vectors with safety features
Oxford BioMedica’s LentiVector® platform is designed to give the highest safety and efficacy.
Automation and robotics
The LentiVector® platform integrates automated systems enabling scalable and cost-effective manufacture of lentiviral vectors.
200L serum-free suspension cell culture
Oxford BioMedica established serum-free suspension production processes to enhance vector output.